Fate Therapeutics Inc.
Clinical‑stage biopharma Fate Therapeutics develops off‑the‑shelf CAR‑NK/T cell therapies for high‑need cancers and immune diseases, with candidates like FT576 (multiple myeloma) and FT825 (solid tumors), backed by collaborations with Ono, Juno and Janssen.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 181
- HQ: San Diego
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.